These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 12901155

  • 1. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
    Zonder JA, Schiffer CA.
    Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM, Talpaz M.
    Semin Oncol; 2001 Oct 15; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [Abstract] [Full Text] [Related]

  • 12. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D.
    Med Hypotheses; 2008 Oct 15; 70(1):128-36. PubMed ID: 17566666
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J.
    Haematologica; 2003 Nov 15; 88(11):1213-20. PubMed ID: 14607749
    [Abstract] [Full Text] [Related]

  • 15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P.
    J Assoc Physicians India; 2005 Apr 01; 53():291-5. PubMed ID: 15987013
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.
    Cancer; 2003 Sep 15; 98(6):1105-13. PubMed ID: 12973833
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.